Vitamin D Cognitive Function Meta-analysis: What the Evidence Says

Quick Answer

Vitamin D Cognitive Function Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 systematic review.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• ω Current pharmacological treatments for MCI, such as cholinesterase inhibitors and memantine, have shown limited effectiveness in delaying disease progression and are frequently associated with adverse effects, which contribute to poor patient adherence. [Wang Xiaolong (2026); evidence level 1]
• ω During the onset and progression of MCI, several physiological biomarkers, including reduced BDNF levels (reflecting impaired neurogenesis), elevated amyloid-β peptides (Aβ42 and Aβ40), and abnormal oxidative stress markers, serve as objective indicators for evaluating intervention efficacy. [Wang Xiaolong (2026); evidence level 1]
• Over 40% of patients develop moderate to severe neurological disability and approximately 35% suffer from cognitive impairment, which significantly affects their long-term quality of life.According to emerging evidence, nutritional and metabolic statuses may influence stroke prognosis beyond traditional vascular risk factors. [Zhou Yinjuan (2026); evidence level 1]
• For instance, Zeng et&#160;al.have reported that serum vitamin D levels <38.4&#8201;nmol/L are significantly associated with poor 5-year prognosis (odds ratio (OR)&#8201;=&#8201;6.36). [Zhou Yinjuan (2026); evidence level 1]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For vitamin d cognitive function meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Wang Xiaolong (2026). Effects of dietary supplements on cognitive outcomes and physiological biomarkers in mild cognitive impairment: a systematic review and network meta-analysis. DOI: 10.3389/fnut.2026.1775177. PMCID: PMC13167511. PMID: 42137868. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13167511/
• Zhou Yinjuan (2026). Association between serum vitamin D levels and functional outcomes in ischemic stroke patients: A systematic review and meta-analysis. DOI: 10.1177/03000605261438342. PMCID: PMC13080135. PMID: 41968082. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13080135/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.